LPL Financial’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

LPL Financial’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,527	Closed	-$7.58K	–	4628
2022 Q4	$7.58K	Hold	10,527	–	–	﹤0.01%	4427
2022 Q3	$13K	Buy	10,527 +25	+0.2%	+$32	﹤0.01%	4359
2022 Q2	$12K	Sell	10,502 -790	-7%	-$1.19K	﹤0.01%	4377
2022 Q1	$24K	Buy	+11,292	New	+$18.4K	﹤0.01%	4111
2021 Q4	–	Sell	-28,548	Closed	-$83K	–	4486
2021 Q3	$83K	Sell	28,548 -910	-3%	-$2.77K	﹤0.01%	4177
2021 Q2	$97K	Buy	29,458 +12,760	+76%	+$40.9K	﹤0.01%	4069
2021 Q1	$63K	Buy	+16,698	New	+$72.6K	﹤0.01%	3975
2018 Q4	–	Sell	-1,193	Closed	-$74K	–	3283
2018 Q3	$74K	Sell	1,193 -488	-29%	-$33K	﹤0.01%	3144
2018 Q2	$124K	Sell	1,681 -22	-1%	-$1.72K	﹤0.01%	3086
2018 Q1	$112K	Buy	1,703 +40	+2%	+$3.02K	﹤0.01%	3062
2017 Q4	$140K	Buy	+1,663	New	+$163K	﹤0.01%	2891

Other funds holding BLCM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LPL Financial's BLCM Position: Q1 2023 in Review

LPL Financial sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2023, closing a stake of 10,527 shares — an estimated $7.58K sold.

LPL Financial first reported a position in BLCM in Q4 2017 and held it in 11 quarters. The position peaked at $140K in Q4 2017. 25 funds tracked by Wall St. Rank hold BLCM as of Q1 2023.

LPL Financial reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
LPL Financial sold 10,527 Bellicum Pharmaceuticals, Inc. shares in Q1 2023, an estimated $7.58K.
LPL Financial first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2017 and held it in 11 quarters.
LPL Financial's Bellicum Pharmaceuticals, Inc. position peaked at $140K in Q4 2017.
25 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2023.

Based on LPL Financial's 13F filing for Q1 2023, filed 10 May 2023.